MedWatch

Covid-19 challenges US dreams for Copenhagen-based diagnostics company

In spite of Covid-19, the plans to launch in the US in 2020 is still on the table for Radiobiotics, which develops algorithms for detecting diseases on X-ray scans. The firm has entered into a new US partnership, and before the new year, it will submit an FDA application and kick off the commercialization process.

From the left: CTO Pavel Lisouski, COO Stine Mølgaard Sørensen, CEO Mads Jarner Brevadt and CSO Martin Axelsen. All co-founders of Radiobiotics. | Foto: Radiobotics / PR

Like most other companies, the digital health firm Radiobiotics from Copenhagen has been struck by the effects of the Covid-19 virus.

The company was established just under two years ago. With the use of artificial intelligence, it aims to help radiologists pinpoint signs of disease. However, the company has been challenged by Covid-19 limitations. The US, especially, which was announced as the firm's next big growth market in spring, has proven troublesome.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Biontech-direktører: Derfor måtte Afrika vente på coronavacciner

Tyske Biontech vil bruge de mange corona-milliarder på at hjælpe lande i Afrika med at komme både coronavirus, malaria og turberkulose til livs, men alligevel stod kontinentet langt nede i køen, da de første coronavacciner skulle distribueres. MedWatch har spurgt hvorfor.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier